About Tavros
Tavros is a company based in Durham (United States) founded in 2019 by Kris Wood was acquired by Vividion Therapeutics in January 2025.. Tavros has raised $8.5 million across 2 funding rounds from investors including ARE, Vividion Therapeutics and Piedmont Capital. The company has 13 employees as of December 31, 2022. Tavros offers products and services including Chemoproteomics Platform. Tavros operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Durham, United States
- Employees 13 as on 31 Dec, 2022
- Founders Kris Wood
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$8.5 M (USD)
in 2 rounds
-
Latest Funding Round
$7.5 M (USD), Seed
Sep 27, 2022
-
Investors
ARE
& 3 more
-
Employee Count
13
as on Dec 31, 2022
-
Acquired by
Vividion Therapeutics
(Jan 08, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Tavros
Tavros offers a comprehensive portfolio of products and services, including Chemoproteomics Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform identifies novel therapeutics for undrugged disease targets using advanced chemistry.
Funding Insights of Tavros
Tavros has successfully raised a total of $8.5M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $7.5 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Seed — $7.5M
-
First Round
First Round
(02 Mar 2020)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Seed - Tavros | Valuation | Piedmont Capital , KdT Ventures | |
| Mar, 2020 | Amount | Seed - Tavros | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Tavros
Tavros has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Vividion Therapeutics and Piedmont Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Commercial loans are brokered by Piedmont Capital for investors.
|
Founded Year | Domain | Location | |
|
Early-stage investments are made in frontier science ventures.
|
Founded Year | Domain | Location | |
|
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Tavros
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Tavros
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tavros Comparisons
Competitors of Tavros
Tavros operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tavros
Frequently Asked Questions about Tavros
When was Tavros founded?
Tavros was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is Tavros located?
Tavros is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Is Tavros a funded company?
Tavros is a funded company, having raised a total of $8.5M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1000K, raised on Mar 02, 2020.
How many employees does Tavros have?
As of Dec 31, 2022, the latest employee count at Tavros is 13.
What does Tavros do?
Tavros was founded in 2019 and is based in Durham, United States. Small-molecule therapeutics targeting cancer are developed through a high-throughput functional genomics discovery platform. Predictive biomarkers and drug combinations are incorporated into the drug development process. Operations focus on oncology within the biotechnology sector, supporting targeted therapeutic advancements.
Who are the top competitors of Tavros?
Tavros's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Tavros offer?
Tavros offers Chemoproteomics Platform.
Who are Tavros's investors?
Tavros has 4 investors. Key investors include ARE, Vividion Therapeutics, Piedmont Capital, and KdT Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.